Cim Investment Mangement Inc. Has $1.21 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)

Cim Investment Mangement Inc. lifted its stake in Merck & Co., Inc. (NYSE:MRK) by 3.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,707 shares of the company’s stock after purchasing an additional 494 shares during the quarter. Merck & Co., Inc. accounts for about 0.6% of Cim Investment Mangement Inc.’s investment portfolio, making the stock its 22nd largest holding. Cim Investment Mangement Inc.’s holdings in Merck & Co., Inc. were worth $1,208,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in MRK. Banco Santander S.A. lifted its stake in Merck & Co., Inc. by 11.4% in the 1st quarter. Banco Santander S.A. now owns 271,617 shares of the company’s stock worth $20,899,000 after acquiring an additional 27,758 shares in the last quarter. Shoker Investment Counsel Inc. lifted its stake in Merck & Co., Inc. by 1.9% in the 4th quarter. Shoker Investment Counsel Inc. now owns 22,031 shares of the company’s stock worth $2,003,000 after acquiring an additional 417 shares in the last quarter. Eagle Global Advisors LLC lifted its stake in Merck & Co., Inc. by 0.9% in the 1st quarter. Eagle Global Advisors LLC now owns 159,139 shares of the company’s stock worth $12,244,000 after acquiring an additional 1,407 shares in the last quarter. Benjamin Edwards Inc. lifted its stake in Merck & Co., Inc. by 319.3% in the 1st quarter. Benjamin Edwards Inc. now owns 8,331 shares of the company’s stock worth $641,000 after acquiring an additional 6,344 shares in the last quarter. Finally, Ameraudi Asset Management Inc. purchased a new stake in Merck & Co., Inc. in the 4th quarter worth about $290,000. Institutional investors and hedge funds own 74.33% of the company’s stock.

Several brokerages recently issued reports on MRK. Credit Suisse Group reissued a “buy” rating and issued a $95.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, May 4th. Argus cut their price target on Merck & Co., Inc. from $105.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. UBS Group cut their price target on Merck & Co., Inc. from $96.00 to $92.00 and set a “buy” rating for the company in a research note on Monday, April 13th. SVB Leerink cut their price target on Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating for the company in a research note on Wednesday, April 29th. Finally, Royal Bank of Canada cut their price target on Merck & Co., Inc. from $92.00 to $89.00 and set a “sector perform” rating for the company in a research note on Wednesday, April 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Merck & Co., Inc. presently has an average rating of “Buy” and a consensus price target of $94.15.

Shares of NYSE MRK traded up $0.37 during mid-day trading on Tuesday, reaching $77.12. 10,448,801 shares of the company traded hands, compared to its average volume of 12,513,424. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.87 and a current ratio of 1.11. The stock has a market cap of $196.63 billion, a PE ratio of 19.43, a price-to-earnings-growth ratio of 2.17 and a beta of 0.50. The company’s fifty day moving average is $78.40 and its two-hundred day moving average is $82.37. Merck & Co., Inc. has a fifty-two week low of $65.25 and a fifty-two week high of $92.64.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $1.50 EPS for the quarter, beating the Zacks’ consensus estimate of $1.34 by $0.16. The business had revenue of $12.06 billion for the quarter, compared to analyst estimates of $11.46 billion. Merck & Co., Inc. had a return on equity of 52.46% and a net margin of 21.10%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.22 EPS. Research analysts forecast that Merck & Co., Inc. will post 5.31 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 15th will be issued a $0.61 dividend. This represents a $2.44 dividend on an annualized basis and a yield of 3.16%. The ex-dividend date of this dividend is Friday, June 12th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 47.01%.

In other Merck & Co., Inc. news, Director Wendell P. Weeks sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $76.02, for a total value of $380,100.00. Following the sale, the director now owns 5,100 shares of the company’s stock, valued at approximately $387,702. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.28% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Average Daily Trade Volume – What You Need to Know

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.